IBAB Ion Beam Applications SA

IBA - Regulated Information

IBA - Regulated Information

IBA SA - Regulated information



                                                                                                                        November 28th 5:45 pm



Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007 ) (hereinafter, the “Law”)

 

Under this provision:

"[...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by category, the number of securities conferring the right to vote and voting rights vote, at the latest at the end of each calendar month in which an increase or a decrease in these numbers occurred.

On each publication referred to in the first paragraph, the issuer also mentions, if applicable, the total number of bonds convertible into securities conferring the right to vote and rights materialized or not by securities to the subscription of securities conferring the right to vote not yet issued, the total number of voting rights that would result from the exercise of these conversion or subscription rights and the total number of shares without voting rights. "

The following information are current as of November 09th ,2022

Nature of information  Remark
Amount of capital (EUR)42.502.318,54 
Securities with voting rights =(A)30.282.218This is the basis for calculating the 30% threshold provided in article 5 of the takeover law of April 1, 2007 (Belgian Gazette 26.IV.2007)
Shares with voting rights30.282.218 
Shares with loyalty voting right (section 28 of the articles of association) =(B)8.120.827 
Existing voting rights =[A-B+(B*2)]38.403.045This is the denominator under which must be calculated the quota of voting rights that can give rise to notification in accordance with article 6 of the Law
Bonds convertible into shares (CB)0 
Voting rights that would result of CB conversion0 
Subscription rights (warrants) issued and exercisable20.000 
Voting rights that would result of warrant conversion20.000 
Statutory and legal thresholds (section 35 of the articles of association)1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, etc. par tranche de 5%These are the thresholds under which the crossing, whether upward or downward (including passive crossing), gives rise to notification in accordance with section 6 or 18, §2, of the Law.

Contact person for threshold crossing notifications: .

Shares endowed with the right to vote in loyalty: registered shares recorded in the share register for at least two consecutive years in the name of their holder (section 28 of the articles of association, in accordance with section 7:53 of the Companies and Associations Code).

Following the introduction of the loyalty voting right by decision of the general meeting of March 10, 2020, the calculation method used by IBA to determine the number of shares with the loyalty voting right at any time is the LIFO method (last in, first out), namely: for the same registered shareholder, the shares which the latter most recently acquired are the first shares which will be deducted from his “basket” of registered shares if he transfer shares thereafter.

Statutory ceiling (section 7, paragraph 1, of the articles of association: “No shareholder may, with companies and persons related to him, participate in the voting at general meetings for a number of votes exceeding 35% of the votes attached to all of the shares with voting rights issued by the company”): currently 35% of 38.339.545, i.e. 13.418.840,8 votes.

ISIN Code : Euronext Brussels BE0003766806

 

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,800 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

For further information, please contact:

IBA

Marie Sirault

Paralegal



 

______________________

 

Attachment



EN
28/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ackermans & van Haaren: Expect buoyed contribution from Private Banking. ASR: 1H: strong solvency, buyouts at 12% IRR. Deceuninck: Weak set of results, as expected following the change in CEO. EVS: Very weak 1H25, but guidance unchanged; convincing bolt-on deal in the US. IBA: IBA to install one P1 system at university campus in Heidelberg, Germany. NEPI Rockcastle: Robust performance, small upward revision to guidance

Guy Sips ... (+7)
  • Guy Sips
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Heidelberg University Hospital expands its particle therapy program wi...

Heidelberg University Hospital expands its particle therapy program with IBA’s Proteus®ONE solution Louvain-La-Neuve, Belgium, August 20, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer and Heidelberg University Hospital (Universitätsklinikum Heidelberg AöR, UKHD) announce today that they have signed a contract to install a Proteus®ONE1 compact proton therapy solution to be located on the University campus in Heidelberg, Germany. The first payment ...

 PRESS RELEASE

L'hôpital universitaire de Heidelberg élargit son programme de thérapi...

L'hôpital universitaire de Heidelberg élargit son programme de thérapie par particules avec une solution Proteus®ONE Louvain-la-Neuve, Belgique, le 20 août 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, et l'hôpital universitaire de Heidelberg (Universitätsklinikum Heidelberg AöR, UKHD) annoncent aujourd'hui la signature d'un contrat pour l'installation d'une solution compacte de protonthérapie Proteus®ONE1  sur le campus universitaire...

 PRESS RELEASE

IBA Notice of Half Year 2025 Results and Conference Call

IBA Notice of Half Year 2025 Results and Conference Call HY25 results webcast to take place on Thursday, 28 August 2025 at 3pm CEST Louvain-la-Neuve, Belgium, 07 August 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2025 on Thursday, 28 August 2025 at 7am CEST. Conference Call Information IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The con...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch